Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma

Highlights • We conducted a systematic review for renal cell carcinoma treatment in elderly patients. • Risks of different treatment modalities are influenced more by age than efficacy is. • Relatively little attention is paid to elderly patients in RCC studies.

Saved in:
Bibliographic Details
Published inCancer treatment reviews Vol. 46; pp. 63 - 72
Main Authors van den Brom, R.R.H, van Es, S.C, Leliveld, A.M, Gietema, J.A, Hospers, G.A.P, de Jong, I.J, de Vries, E.G.E, Oosting, S.F
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.05.2016
Subjects
Age Factors
Aged
Aged, 80 and over
Angiogenesis inhibitors
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Elderly
Hematology, Oncology and Palliative Medicine
Humans
Immunotherapy
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Kidney Neoplasms - therapy
Mammalian target of rapamycin inhibitors
Neoplasm Metastasis
Nephrectomy
Programmed death 1
Randomized Controlled Trials as Topic
Renal cell carcinoma
Programmed death 1
Nephrectomy
Renal cell carcinoma
Immunotherapy
Mammalian target of rapamycin inhibitors
Angiogenesis inhibitors
Elderly
Online AccessGet full text

Cover

More Information
Summary:Highlights • We conducted a systematic review for renal cell carcinoma treatment in elderly patients. • Risks of different treatment modalities are influenced more by age than efficacy is. • Relatively little attention is paid to elderly patients in RCC studies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2016.04.002